Beyond Antibiotics: The Emerging Role of Probiotics in H. pylori Management

One in every two people worldwide harbors Helicobacter pylori, a stomach pathogen that becomes problematic when it damages and inflames the gastric lining. A substantial body of research shows that H. pylori can dominate the stomach microbiota. This can increase Proteobacteria while reducing microbial diversity and disrupting commensal balance. Such changes have been linked to gastritis, ulcer formation, and progression to neoplastic disease.

Probiotic interventions aimed at restoring microbial balance have been explored as a way to improve clinical outcomes. This IPA blog reviews H. pylori infection, its mechanisms of action, and the evidence supporting probiotic supplementation as an adjunctive therapy.

Helicobacter pylori, in brief

H. pylori infects the epithelial lining of the stomach in approximately half of the global population —an estimated four billion individuals. The bacterium uses flagella for motility and urease to survive gastric acid, enabling colonization. Its virulence factors—including adhesion proteins, immune-modulating mechanisms, and adaptive capabilities—support persistent infection in the gastric environment.

The infection typically begins in childhood and induces lifelong, progressive gastric inflammation that can lead to a variety of diseases, such as gastritis, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue lymphoma.

Whether the infected individuals go on to develop serious conditions depends on a complex interplay between the host and the bacterium. Host genetics and gastric acid secretion largely determine its ability to colonize or dominate the gastric niche.

Interestingly, emerging evidence suggests an inverse relationship between H. pylori infection and allergic diseases, with some studies proposing that early-life colonization may modulate immune development in ways that reduce the risk of asthma and other atopic conditions.

Associated diseases

Chronic gastritis—persistent inflammation of the stomach lining—is strongly associated with H. pylori infection and is observed in the vast majority of infected individuals.

Peptic ulcer disease—characterized by open sores in the lining of the stomach or duodenum—occurs in about 10% of individuals colonized with H. pylori, which is the primary driver of the condition and is responsible for roughly 90% of duodenal ulcers and 70–90% of gastric ulcers.

Gastric cancer —a major cause of cancer-related death —correlates strongly with H. pylori infection, which has been recognized as a class 1 carcinogen since 1994. Note that cancer risk is further influenced by lifestyle factors such as smoking, heavy alcohol use, high salt intake, processed meat consumption, and low fruit intake, as well as host genetics. However, disease progression varies widely depending on individual immune responses, bacterial virulence, and environmental exposures, with infection and cancer rates differing substantially across geographic regions.

Gastric mucosa-associated tissue lymphoma is a rare mature B-cell neoplasm associated with H. pylori infection. H. pylori eradication is effective in treating approximately 75% of patients with early stage gastric lymphoma. 

Treatment

Since 2017, international consensus guidelines recommend that H. pylori be eradicated promptly upon diagnosis. Standard therapy consists of triple or quadruple regimens over 7–14 days: a proton-pump inhibitor with two antibiotics (clarithromycin plus amoxicillin or metronidazole), optionally with bismuth salts.

However, over the past two decades, rising antibiotic resistance in H. pylori has driven a steady decline in eradication success rates. Compounding this, antibiotic-related side effects—including diarrhea, nausea, and vomiting—reduce patient compliance, further undermining standard therapy outcomes.

As we shall see, H. pylori infection also reshapes the gastric microbial ecosystem, which in turn affects outcomes.

The microbiome and H. pylori

The stomach contains a dynamic microbial ecosystem that H. pylori can overtake during chronic infection, reducing microbial diversity and driving dysbiosis linked to gastritis, ulcers, and gastric cancer. In healthy, H. pylori-negative individuals, this ecosystem is more diverse and stable. With infection, that balance shifts. H. pylori becomes dominant, and overall microbial richness declines. This shift reflects not only direct bacterial competition but also host immune responses. Inflammation recruits immune cells that further disrupt the resident microbiota and reinforce dysbiosis.

H. pylori colonization occurs within a broader microbial environment, where interactions among microbes can be both inhibitory and supportive of H. pylori. Certain commensal bacteria may help suppress H. pylori growth or modulate inflammation, while other microbes may contribute to disease progression.

The pathogenicity of H. pylori is also shaped by strain-specific virulence factors that promote inflammation, epithelial damage, and further alterations in microbial ecology.

As infection persists, gastric physiology shifts—acidity may decline, immune signaling changes, and nutrient availability is altered—further influencing microbial composition and function.

This bidirectional relationship between H. pylori, the host, and the microbiome helps sustain chronic infection and disease progression, while also providing a rationale for exploring probiotic interventions aimed at restoring microbial balance and improving clinical outcomes.

Probiotic interventions and H. pylori

Probiotic interventions have been investigated as adjunctive strategies.

They may help counter H. pylori through several complementary mechanisms: they compete with the pathogen for adhesion to the gastric lining, enhance mucosal barrier function and mucin production, and secrete antimicrobial compounds such as short-chain fatty acids that can inhibit bacterial growth. At the same time, they modulate the immune response—reducing inflammation while promoting protective pathways—and may enhance the effectiveness of antibiotic therapy, collectively improving the gastric environment and limiting H. pylori colonization and its associated complications.

An umbrella meta-analysis of 18 meta-analyses found that adding probiotics to standard therapy, compared with standard treatment alone, modestly but significantly improves H. pylori eradication rates and reduces treatment-related side effects. Benefits appear to be dose-dependent, with higher CFU counts and multi-strain formulations showing the most consistent effects.”

This highlights the potential for tailoring probiotic supplementation based on genus-specific effects, although efficacy remains highly strain-specific, and not all strains within a genus confer the same benefits.

A separate umbrella meta-analysis of 28 meta-analyses similarly found that probiotic supplementation improves eradication rates and reduces side effects compared to standard therapy alone, with broadly comparable results for single- and multi-strain formulations.

By modulating the gastrointestinal microbiota, probiotic supplementation may help address rising antibiotic resistance, the chief cause of treatment failure. In addition, their ability to reduce common side effects—such as diarrhea, nausea, and vomiting—may improve adherence to therapy.

Further research is needed to clarify the influence of confounding factors such as diet (including prebiotic intake), lifestyle, and antibiotic exposure on the microbiome and H. pylori infection dynamics. Building on this, key priorities moving forward include identifying the most effective probiotic strains, defining optimal dosing and duration, improving study consistency, accounting for patient variability, and clarifying underlying mechanisms as well as long-term effects in H. pylori management.

A recent review concluded: “probiotics supplementation is a plausible adjunctive strategy in the management of H. pylori, with potential benefits in terms of eradication rates improvement and side effects reduction. Until rigorous evidence is available, clinicians should consider probiotics as a promising, albeit not definitively proven, adjunct to H. pylori eradication therapy.”

Although eradication is the preferred treatment, with an estimated four billion people infected by H. pylori, this may not be feasible. Additional solutions are required. Here, probiotics can play a role as well, not to eradicate but to keep H. pylori infection under control, minimizing risk for H. pylori-associated diseases.

Takeaway

Helicobacter pylori doesn’t act alone—it reshapes the entire gastric microbiome. As it becomes dominant, microbial diversity declines, inflammation rises, and the risk of ulcers and cancer increases.

Probiotics may offer a practical counterbalance. Evidence from multiple umbrella meta-analyses suggests that specific strains—particularly Lactobacillus and Bifidobacterium—can modestly improve eradication rates while reducing treatment side effects, likely by supporting microbial balance, strengthening the mucosal barrier, and modulating immune responses.

Though not a cure-all, probiotic supplementation may be a promising adjunct. As research evolves, more precise, strain-targeted approaches may help turn the microbiome from a casualty of H. pylori infection into part of the solution.

Image by Arek Socha from Pixabay

Key references

“Schistosomes, liver flukes and Helicobacter pylori.” IARC monographs on the evaluation of carcinogenic risks to humans vol. 61 (1994): 1-241.

Balakrishnan, Maya et al. “Changing Trends in Stomach Cancer Throughout the World.” Current gastroenterology reports vol. 19,8 (2017): 36. doi:10.1007/s11894-017-0575-8

Brawner, Kyle M et al. “Gastric microbiome and gastric cancer.” Cancer journal (Sudbury, Mass.) vol. 20,3 (2014): 211-6. doi:10.1097/PPO.0000000000000043

Cao, Xinyuan et al. “Impact of Helicobacter pylori on the gastric microbiome in patients with chronic gastritis: a systematic review and meta-analysis protocol.” BMJ open vol. 13,3 e050476. 16 Mar. 2023, doi:10.1136/bmjopen-2021-050476

Chey, William D et al. “ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.” The American journal of gastroenterology vol. 112,2 (2017): 212-239. doi:10.1038/ajg.2016.563

Clyne, Marguerite, and Tadhg Ó Cróinín. “Pathogenicity and virulence of Helicobacter pylori: A paradigm of chronic infection.” Virulence vol. 16,1 (2025): 2438735. doi:10.1080/21505594.2024.2438735

Dascălu, Raluca Ioana et al. “Multidrug resistance in Helicobacter pylori infection.” Frontiers in microbiology vol. 14 1128497. 27 Feb. 2023, doi:10.3389/fmicb.2023.1128497

Hooi, James K Y et al. “Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.” Gastroenterology vol. 153,2 (2017): 420-429. doi:10.1053/j.gastro.2017.04.022

Hu, Qinglong et al. “Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management.” Biomarker research vol. 4 15. 27 Jul. 2016, doi:10.1186/s40364-016-0068-1

Liang, Bing et al. “Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics.” Frontiers in cellular and infection microbiology vol. 12 1042070. 25 Nov. 2022, doi:10.3389/fcimb.2022.1042070

Liu, Mengmeng et al. “Update on the association between Helicobacter pylori infection and asthma in terms of microbiota and immunity.” Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 20,1 4. 14 Jan. 2024, doi:10.1186/s13223-024-00870-2

Liu, Xin, and Kent-Man Chu. “E-cadherin and gastric cancer: cause, consequence, and applications.” BioMed research international vol. 2014 (2014): 637308. doi:10.1155/2014/637308

Musazadeh, Vali et al. “The effectiveness of treatment with probiotics in Helicobacter pylori eradication: results from an umbrella meta-analysis on meta-analyses of randomized controlled trials.” Food & function vol. 14,16 7654-7662. 14 Aug. 2023, doi:10.1039/d3fo00300k

Shadvar, Neda et al. “A review for non-antibiotic treatment of Helicobacter pylori: new insight.” Frontiers in microbiology vol. 15 1379209. 7 May. 2024, doi:10.3389/fmicb.2024.1379209

Shirani, Maryam et al. “The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis.” BMC infectious diseases vol. 23,1 543. 19 Aug. 2023, doi:10.1186/s12879-023-08504-5

Tshibangu-Kabamba, Evariste, and Yoshio Yamaoka. “Helicobacter pylori infection and antibiotic resistance – from biology to clinical implications.” Nature reviews. Gastroenterology & hepatology vol. 18,9 (2021): 613-629. doi:10.1038/s41575-021-00449-x

Verma, Jagriti et al. “The Influence of Gastric Microbiota and Probiotics in Helicobacter pylori Infection and Associated Diseases.” Biomedicines vol. 13,1 61. 30 Dec. 2024, doi:10.3390/biomedicines13010061

Yang, Zihan et al. “The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses.” Scientific reports vol. 14,1 10069. 2 May. 2024, doi:10.1038/s41598-024-59399-4

Yuan, Lin et al. “Beyond antibiotics: probiotics as a promising ally against Helicobacter pylori.” Frontiers in pharmacology vol. 16 1620870. 11 Jul. 2025, doi:10.3389/fphar.2025.1620870

Zullo, Angelo et al. “Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 8,2 (2010): 105-10. doi:10.1016/j.cgh.2009.07.017